Home Stock

Stock Research: Genmab

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Genmab

CPH:GMAB DK0010272202
98
  • Value
    50
  • Growth
    62
  • Safety
    Safety
    95
  • Combined
    92
  • Sentiment
    94
  • 360° View
    360° View
    98
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Genmab A/S is a biotechnology company specializing in antibody therapeutics for cancer treatment. The company operates in the biotechnology industry and creates antibody therapeutics such as DARZALEX, Kesimpta, TEPEZZA, and FASPRO. Genmab operates internationally, with its approved therapies available in various regions. In the last fiscal year, the company had a market cap of $14,027 million, profits of $2,979 million, revenue of $3,122 million, and 2682 employees.

more
Strongest Rank Dividend Yield
Weakest Rank 360° View
Country Denmark
Industry Biotechnology
Size Large
Website genmab.com
Index
OMX C20
NASDAQ
Genmab stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
50 18 3 1
Growth
62 42 57 51
Safety
Safety
95 100 98 90
Sentiment
94 48 56 52
360° View
360° View
98 56 51 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
13 31 36 39
Opinions Change
84 60 74 53
Pro Holdings
n/a 65 65 68
Market Pulse
71 54 43 41
Sentiment
94 48 56 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
50 18 3 1
Growth
62 42 57 51
Safety Safety
95 100 98 90
Combined
92 72 58 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
55 11 9 3
Price vs. Earnings (P/E)
40 47 17 10
Price vs. Book (P/B)
44 42 19 8
Dividend Yield
1 1 1 1
Value
50 18 3 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
43 83 75 82
Profit Growth
46 21 28 8
Capital Growth
55 67 88 83
Stock Returns
67 18 22 32
Growth
62 42 57 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
56 90 92 89
Refinancing
56 58 71 56
Liquidity
98 92 94 98
Safety Safety
95 100 98 90

Similar Stocks

Discover high‑ranked alternatives to Genmab and broaden your portfolio horizons.

STMicroelectronics

PAR:STMPA
Country: Netherlands
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Krka

LJU:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

MOL

BUD:MOL
Country: Hungary
Industry: Oil & Gas Integrated
Size: X-Large
Full Stock Analysis

Ternium

NYQ:TX
Country: Netherlands
Industry: Steel
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews